{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:20:47Z","timestamp":1790760047807,"version":"4.1.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T00:00:00Z","timestamp":1628812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T00:00:00Z","timestamp":1628812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["5TR00, 5TR019 and MCA\/600)"],"award-info":[{"award-number":["5TR00, 5TR019 and MCA\/600)"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000351","name":"British Lung Foundation","doi-asserted-by":"publisher","award":["CSOBLFRG16-2 and MKMRGPG18"],"award-info":[{"award-number":["CSOBLFRG16-2 and MKMRGPG18"]}],"id":[{"id":"10.13039\/501100000351","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["A17196, A21139 and A29252"],"award-info":[{"award-number":["A17196, A21139 and A29252"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Malignant mesothelioma (MpM) is an aggressive, invariably fatal tumour that is causally linked with asbestos exposure. The disease primarily results from loss of tumour suppressor gene function and there are no \u2018druggable\u2019 driver oncogenes associated with MpM. To identify opportunities for management of this disease we have carried out polysome profiling to define the MpM translatome. We show that in MpM there is a selective increase in the translation of mRNAs encoding proteins required for ribosome assembly and mitochondrial biogenesis. This results in an enhanced rate of mRNA translation, abnormal mitochondrial morphology and oxygen consumption, and a reprogramming of metabolic outputs. These alterations delimit the cellular capacity for protein biosynthesis, accelerate growth and drive disease progression. Importantly, we show that inhibition of mRNA translation, particularly through combined pharmacological targeting of mTORC1 and 2, reverses these changes and inhibits malignant cell growth in vitro and in ex-vivo tumour tissue from patients with end-stage disease. Critically, we show that these pharmacological interventions prolong survival in animal models of asbestos-induced mesothelioma, providing the basis for a targeted, viable therapeutic option for patients with this incurable disease.<\/jats:p>","DOI":"10.1038\/s41467-021-25173-7","type":"journal-article","created":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T06:02:51Z","timestamp":1628834571000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["The pathogenesis of mesothelioma is driven by a dysregulated translatome"],"prefix":"10.1038","volume":"12","author":[{"given":"Stefano","family":"Grosso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7222-9056","authenticated-orcid":false,"given":"Alberto","family":"Marini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Gyuraszova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan Vande","family":"Voorde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aristeidis","family":"Sfakianos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin D.","family":"Garland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2849-612X","authenticated-orcid":false,"given":"Angela Rubio","family":"Tenor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Mordue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Chernova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7672-158X","authenticated-orcid":false,"given":"Nobu","family":"Morone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4573-9303","authenticated-orcid":false,"given":"Marco","family":"Sereno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6401-2014","authenticated-orcid":false,"given":"Claire P.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3690-2386","authenticated-orcid":false,"given":"Leah","family":"Officer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3202-6208","authenticated-orcid":false,"given":"Pooyeh","family":"Farahmand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Rooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9004-4079","authenticated-orcid":false,"given":"David","family":"Sumpton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhumita","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1386-6730","authenticated-orcid":false,"given":"Ana","family":"Teod\u00f3sio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Ficken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Guerra","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth V.","family":"Spriggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Ming","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bushell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9540-3010","authenticated-orcid":false,"given":"Owen J.","family":"Sansom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5538-5468","authenticated-orcid":false,"given":"Daniel","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7886-1159","authenticated-orcid":false,"given":"Marion","family":"MacFarlane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3552-7446","authenticated-orcid":false,"given":"John P. C.","family":"Le Quesne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1470-8531","authenticated-orcid":false,"given":"Anne E.","family":"Willis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,13]]},"reference":[{"key":"25173_CR1","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1093\/occmed\/kqs119","volume":"62","author":"A Darnton","year":"2012","unstructured":"Darnton, A., Hodgson, J., Benson, P. & Coggon, D. Mortality from asbestosis and mesothelioma in Britain by birth cohort. Occup. Med. (Lond.) 62, 549\u2013552 (2012).","journal-title":"Occup. Med. (Lond.)"},{"key":"25173_CR2","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1038\/sj.bjc.6604879","volume":"100","author":"C Rake","year":"2009","unstructured":"Rake, C. et al. Occupational, domestic and environmental mesothelioma risks in the British population: a case-control study. Br. J. Cancer 100, 1175\u20131183 (2009).","journal-title":"Br. J. Cancer"},{"key":"25173_CR3","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/sj.bjc.6605781","volume":"103","author":"E Tan","year":"2010","unstructured":"Tan, E., Warren, N., Darnton, A. J. & Hodgson, J. T. Projection of mesothelioma mortality in Britain using Bayesian methods. Br. J. Cancer 103, 430\u2013436 (2010).","journal-title":"Br. J. Cancer"},{"key":"25173_CR4","doi-asserted-by":"publisher","first-page":"e1000038","DOI":"10.1371\/journal.pbio.1000038","volume":"7","author":"MorrisE Feldman","year":"2009","unstructured":"Feldman, MorrisE., Apsel, Beth, Aino Uotila, R. L., Zachary A, Knight, Davide, Ruggero & Kevan M, Shokat Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 7, e1000038 (2009).","journal-title":"PLoS Biol."},{"key":"25173_CR5","doi-asserted-by":"publisher","first-page":"574","DOI":"10.21037\/tlcr.2018.04.10","volume":"7","author":"CJ de Gooijer","year":"2018","unstructured":"de Gooijer, C. J., Baas, P. & Burgers, J. A. Current chemotherapy strategies in malignant pleural mesothelioma. Transl. Lung cancer Res. 7, 574\u2013583 (2018).","journal-title":"Transl. Lung cancer Res."},{"key":"25173_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.rmed.2017.11.015","volume":"134","author":"KG Blyth","year":"2018","unstructured":"Blyth, K. G. & Murphy, D. J. Progress and challenges in mesothelioma: from bench to bedside. Respir. Med. 134, 31\u201341 (2018).","journal-title":"Respir. Med."},{"key":"25173_CR7","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.jtho.2018.02.021","volume":"13","author":"AJ McCambridge","year":"2018","unstructured":"McCambridge, A. J. et al. Progress in the management of malignant pleural mesothelioma in 2017. J. Thorac. Oncol. 13, 606\u2013623 (2018).","journal-title":"J. Thorac. Oncol."},{"key":"25173_CR8","doi-asserted-by":"publisher","first-page":"S100","DOI":"10.21037\/tlcr.2019.11.23","volume":"9","author":"SG Gray","year":"2020","unstructured":"Gray, S. G. & Mutti, L. Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives. Transl. Lung Cancer Res. 9, S100\u2013s119 (2020).","journal-title":"Transl. Lung Cancer Res."},{"key":"25173_CR9","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1093\/carcin\/bgz066","volume":"40","author":"H Oey","year":"2019","unstructured":"Oey, H. et al. Whole-genome sequencing of human malignant mesothelioma tumours and cell lines. Carcinogenesis 40, 724\u2013734 (2019).","journal-title":"Carcinogenesis"},{"key":"25173_CR10","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.tranon.2018.01.005","volume":"11","author":"JE Kim","year":"2018","unstructured":"Kim, J. E. et al. Mutational profiling of malignant mesothelioma revealed potential therapeutic targets in EGFR and NRAS. Transl. Oncol. 11, 268\u2013274 (2018).","journal-title":"Transl. Oncol."},{"key":"25173_CR11","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng.3520","volume":"48","author":"R Bueno","year":"2016","unstructured":"Bueno, R. et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat. Genet. 48, 407\u2013416 (2016).","journal-title":"Nat. Genet."},{"key":"25173_CR12","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","volume":"8","author":"J Hmeljak","year":"2018","unstructured":"Hmeljak, J. et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov. 8, 1548\u20131565 (2018).","journal-title":"Cancer Discov."},{"key":"25173_CR13","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s13277-013-1210-4","volume":"35","author":"LV de Assis","year":"2014","unstructured":"de Assis, L. V. & Isoldi, M. C. The function, mechanisms, and role of the genes PTEN and TP53 and the effects of asbestos in the development of malignant mesothelioma: a review focused on the genes\u2019 molecular mechanisms. Tumour Biol. 35, 889\u2013901 (2014).","journal-title":"Tumour Biol."},{"key":"25173_CR14","first-page":"1227","volume":"55","author":"Y Sekido","year":"1995","unstructured":"Sekido, Y. et al. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res. 55, 1227\u20131231 (1995).","journal-title":"Cancer Res."},{"key":"25173_CR15","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1038\/cdd.2017.95","volume":"24","author":"A Bononi","year":"2017","unstructured":"Bononi, A. et al. Germline BAP1 mutations induce a Warburg effect. Cell Death Differ. 24, 1694\u20131704 (2017).","journal-title":"Cell Death Differ."},{"key":"25173_CR16","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/ng.855","volume":"43","author":"M Bott","year":"2011","unstructured":"Bott, M. et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat. Genet. 43, 668\u2013672 (2011).","journal-title":"Nat. Genet."},{"key":"25173_CR17","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1158\/0008-5472.CAN-13-2062","volume":"74","author":"CW Menges","year":"2014","unstructured":"Menges, C. W. et al. Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis. Cancer Res. 74, 1261\u20131271 (2014).","journal-title":"Cancer Res."},{"key":"25173_CR18","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1038\/onc.2015.243","volume":"35","author":"A Napolitano","year":"2016","unstructured":"Napolitano, A. et al. Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma. Oncogene 35, 1996\u20132002 (2016).","journal-title":"Oncogene"},{"key":"25173_CR19","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1158\/0008-5472.CAN-15-3371","volume":"76","author":"Y Kadariya","year":"2016","unstructured":"Kadariya, Y. et al. Bap1 is a bona fide tumor suppressor: genetic evidence from mouse models carrying heterozygous germline Bap1 mutations. Cancer Res. 76, 2836\u20132844 (2016).","journal-title":"Cancer Res."},{"key":"25173_CR20","doi-asserted-by":"publisher","first-page":"3302","DOI":"10.1016\/j.cub.2017.09.007","volume":"27","author":"T Chernova","year":"2017","unstructured":"Chernova, T. et al. Long-fiber carbon nanotubes replicate asbestos-induced mesothelioma with disruption of the tumor suppressor gene Cdkn2a (Ink4a\/Arf). Curr. Biol. 27, 3302\u20133314 (2017).","journal-title":"Curr. Biol."},{"key":"25173_CR21","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.gde.2017.10.006","volume":"48","author":"RF Harvey","year":"2018","unstructured":"Harvey, R. F. & Willis, A. E. Post-transcriptional control of stress responses in cancer. Curr. Opin. Genet. Dev. 48, 30\u201335 (2018).","journal-title":"Curr. Opin. Genet. Dev."},{"key":"25173_CR22","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1002\/path.2627","volume":"220","author":"JP Le Quesne","year":"2010","unstructured":"Le Quesne, J. P., Spriggs, K. A., Bushell, M. & Willis, A. E. Dysregulation of protein synthesis and disease. J. Pathol. 220, 140\u2013151 (2010).","journal-title":"J. Pathol."},{"key":"25173_CR23","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1158\/0008-5472.CAN-14-2789","volume":"75","author":"J Pelletier","year":"2015","unstructured":"Pelletier, J., Graff, J., Ruggero, D. & Sonenberg, N. Targeting the eIF4F translation initiation complex: a critical nexus for cancer development. Cancer Res. 75, 250\u2013263 (2015).","journal-title":"Cancer Res."},{"key":"25173_CR24","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1038\/leu.2013.295","volume":"28","author":"E Horvilleur","year":"2014","unstructured":"Horvilleur, E. et al. A role for eukaryotic initiation factor 4B overexpression in the pathogenesis of diffuse large B-cell lymphoma. Leukemia 28, 1092\u20131102 (2014).","journal-title":"Leukemia"},{"key":"25173_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.542","volume":"6","author":"A Modelska","year":"2015","unstructured":"Modelska, A. et al. The malignant phenotype in breast cancer is driven by eIF4A1- mediated changes in the translational landscape. Cell Death Dis. 6, e1603 (2015).","journal-title":"Cell Death Dis."},{"key":"25173_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-25798-7","volume":"8","author":"PK Jaiswal","year":"2018","unstructured":"Jaiswal, P. K., Koul, S., Shanmugam, P. S. T. & Koul, H. K. Eukaryotic translation initiation factor 4 gamma 1 (eIF4G1) is upregulated during prostate cancer progression and modulates cell growth and metastasis. Sci. Rep. 8, 7459 (2018).","journal-title":"Sci. Rep."},{"key":"25173_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.148","volume":"7","author":"T Sbarrato","year":"2016","unstructured":"Sbarrato, T. et al. A ribosome-related signature in peripheral blood CLL B cells is linked to reduced survival following treatment. Cell Death Dis. 7, e2249 (2016).","journal-title":"Cell Death Dis."},{"key":"25173_CR28","first-page":"181","volume":"2","author":"Y Suzuki","year":"2009","unstructured":"Suzuki, Y. et al. Activation of the PI3K-AKT pathway in human malignant mesothelioma cells. Mol. Med. Rep. 2, 181\u2013188 (2009).","journal-title":"Mol. Med. Rep."},{"key":"25173_CR29","doi-asserted-by":"publisher","first-page":"6080","DOI":"10.1038\/sj.onc.1208744","volume":"24","author":"DA Altomare","year":"2005","unstructured":"Altomare, D. A. et al. Human and mouse mesotheliomas exhibit elevated AKT\/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene 24, 6080\u20136089 (2005).","journal-title":"Oncogene"},{"key":"25173_CR30","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1158\/1535-7163.MCT-04-0243","volume":"4","author":"ME Ramos-Nino","year":"2005","unstructured":"Ramos-Nino, M. E. et al. Human mesothelioma cells exhibit tumor cell-specific differences in phosphatidylinositol 3-kinase\/AKT activity that predict the efficacy of onconase. Mol. Cancer Ther. 4, 835\u2013842 (2005).","journal-title":"Mol. Cancer Ther."},{"key":"25173_CR31","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.1128\/MCB.01581-08","volume":"29","author":"MF James","year":"2009","unstructured":"James, M. F. et al. NF2\/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol. Cell Biol. 29, 4250\u20134261 (2009).","journal-title":"Mol. Cell Biol."},{"key":"25173_CR32","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1038\/cdd.2015.165","volume":"23","author":"T Chernova","year":"2016","unstructured":"Chernova, T. et al. Molecular profiling reveals primary mesothelioma cell lines recapitulate human disease. Cell Death Differ. 23, 1152\u20131164 (2016).","journal-title":"Cell Death Differ."},{"key":"25173_CR33","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1101\/gad.339105","volume":"19","author":"SA Mitchell","year":"2005","unstructured":"Mitchell, S. A. et al. Identification of a motif that mediates polypyrimidine tract-binding protein-dependent internal ribosome entry. Genes Dev. 19, 1556\u20131571 (2005).","journal-title":"Genes Dev."},{"key":"25173_CR34","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.cmet.2015.02.010","volume":"21","author":"H Sinvani","year":"2015","unstructured":"Sinvani, H. et al. Translational tolerance of mitochondrial genes to metabolic energy stress involves TISU and eIF1-eIF4GI cooperation in start codon selection. Cell Metab. 21, 479\u2013492 (2015).","journal-title":"Cell Metab."},{"key":"25173_CR35","doi-asserted-by":"publisher","first-page":"37471","DOI":"10.18632\/oncotarget.5462","volume":"6","author":"A Miluzio","year":"2015","unstructured":"Miluzio, A. et al. Expression and activity of eIF6 trigger malignant pleural mesothelioma growth in vivo. Oncotarget 6, 37471\u201337485 (2015).","journal-title":"Oncotarget"},{"key":"25173_CR36","doi-asserted-by":"publisher","first-page":"e29136","DOI":"10.1371\/journal.pone.0029136","volume":"6","author":"S Grosso","year":"2011","unstructured":"Grosso, S. et al. Sensitivity of global translation to mTOR inhibition in REN cells depends on the equilibrium between eIF4E and 4E-BP1. PLoS ONE 6, e29136 (2011).","journal-title":"PLoS ONE"},{"key":"25173_CR37","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1242\/jcs.159186","volume":"129","author":"T MacVicar","year":"2016","unstructured":"MacVicar, T. & Langer, T. OPA1 processing in cell death and disease - the long and short of it. J. Cell Sci. 129, 2297\u20132306 (2016).","journal-title":"J. Cell Sci."},{"key":"25173_CR38","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jbior.2017.11.001","volume":"67","author":"M Leibovitch","year":"2018","unstructured":"Leibovitch, M. & Topisirovic, I. Dysregulation of mRNA translation and energy metabolism in cancer. Adv. Biol. Regul. 67, 30\u201339 (2018).","journal-title":"Adv. Biol. Regul."},{"key":"25173_CR39","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nchembio776","volume":"2","author":"ME Bordeleau","year":"2006","unstructured":"Bordeleau, M. E. et al. Functional characterization of IRESes by an inhibitor of the RNA helicase eIF4A. Nat. Chem. Biol. 2, 213\u2013220 (2006).","journal-title":"Nat. Chem. Biol."},{"key":"25173_CR40","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.cell.2006.11.046","volume":"128","author":"NJ Moerke","year":"2007","unstructured":"Moerke, N. J. et al. Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell 128, 257\u2013267 (2007).","journal-title":"Cell"},{"key":"25173_CR41","doi-asserted-by":"publisher","first-page":"3516","DOI":"10.1021\/acs.jmedchem.7b01795","volume":"61","author":"SH Reich","year":"2018","unstructured":"Reich, S. H. et al. Design of pyridone-aminal eFT508 targeting dysregulated translation by selective mitogen-activated protein kinase interacting kinases 1 and 2 (MNK1\/2) inhibition. J. Med. Chem. 61, 3516\u20133540 (2018).","journal-title":"J. Med. Chem."},{"key":"25173_CR42","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.bmcl.2013.01.019","volume":"23","author":"KG Pike","year":"2013","unstructured":"Pike, K. G. et al. Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014. Bioorg. Med. Chem. Lett. 23, 1212\u20131216 (2013).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"25173_CR43","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1158\/1535-7163.MCT-15-0365","volume":"14","author":"SM Guichard","year":"2015","unstructured":"Guichard, S. M. et al. AZD2014, an inhibitor of mTORC1 and mTORC2, is highly effective in ER+ breast cancer when administered using intermittent or continuous schedules. Mol. Cancer Ther. 14, 2508\u20132518 (2015).","journal-title":"Mol. Cancer Ther."},{"key":"25173_CR44","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/JTO.0000000000000360","volume":"10","author":"SH Ou","year":"2015","unstructured":"Ou, S. H. et al. SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J. Thorac. Oncol. 10, 387\u2013391 (2015).","journal-title":"J. Thorac. Oncol."},{"key":"25173_CR45","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1371\/journal.pbio.1000038","volume":"7","author":"ME Feldman","year":"2009","unstructured":"Feldman, M. E. et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 7, e38 (2009).","journal-title":"PLoS Biol."},{"key":"25173_CR46","doi-asserted-by":"publisher","first-page":"8023","DOI":"10.1074\/jbc.M900301200","volume":"284","author":"CC Thoreen","year":"2009","unstructured":"Thoreen, C. C. et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem. 284, 8023\u20138032 (2009).","journal-title":"J. Biol. Chem."},{"key":"25173_CR47","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1158\/1078-0432.CCR-14-2422","volume":"21","author":"B Basu","year":"2015","unstructured":"Basu, B. et al. First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1\/2 inhibitor AZD2014. Clin. cancer Res. 21, 3412\u20133419 (2015).","journal-title":"Clin. cancer Res."},{"key":"25173_CR48","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1093\/annonc\/mdy245","volume":"29","author":"B Basu","year":"2018","unstructured":"Basu, B. et al. Vistusertib (dual m-TORC1\/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer. Ann. Oncol. 29, 1918\u20131925 (2018).","journal-title":"Ann. Oncol."},{"key":"25173_CR49","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.cell.2015.06.017","volume":"162","author":"W Palm","year":"2015","unstructured":"Palm, W. et al. The utilization of extracellular proteins as nutrients is suppressed by mTORC1. Cell 162, 259\u2013270 (2015).","journal-title":"Cell"},{"key":"25173_CR50","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","volume":"66","author":"KE O\u2019Reilly","year":"2006","unstructured":"O\u2019Reilly, K. E. et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66, 1500\u20131508 (2006).","journal-title":"Cancer Res."},{"key":"25173_CR51","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1158\/1535-7163.MCT-14-0330","volume":"13","author":"E Rozengurt","year":"2014","unstructured":"Rozengurt, E., Soares, H. P. & Sinnet-Smith, J. Suppression of feedback loops mediated by PI3K\/mTOR induces multiple overactivation of compensatory pathways: an unintended consequence leading to drug resistance. Mol. Cancer Ther. 13, 2477\u20132488 (2014).","journal-title":"Mol. Cancer Ther."},{"key":"25173_CR52","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1158\/1535-7163.MCT-18-0183","volume":"17","author":"JT Lynch","year":"2018","unstructured":"Lynch, J. T. et al. Combined inhibition of PI3K\u03b2 and mTOR inhibits growth of PTEN-null tumors. Mol. Cancer Ther. 17, 2309\u20132319 (2018).","journal-title":"Mol. Cancer Ther."},{"key":"25173_CR53","doi-asserted-by":"publisher","first-page":"6911","DOI":"10.1158\/0008-5472.CAN-16-0810","volume":"76","author":"DR Driscoll","year":"2016","unstructured":"Driscoll, D. R. et al. mTORC2 signaling drives the development and progression of pancreatic cancer. Cancer Res. 76, 6911\u20136923 (2016).","journal-title":"Cancer Res."},{"key":"25173_CR54","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1200\/JCO.2017.35.15_suppl.2570","volume":"35","author":"AR Hansen","year":"2017","unstructured":"Hansen, A. R. et al. A first in human phase I study of AZD8186, a potent and selective inhibitor of PI3K in patients with advanced solid tumours as monotherapy and in combination with the dual mTORC1\/2 inhibitor vistusertib (AZD2014) or abiraterone acetate. J. Clin. Oncol. 35, 2570\u20132570 (2017).","journal-title":"J. Clin. Oncol."},{"key":"25173_CR55","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.ccr.2008.01.030","volume":"13","author":"J Jongsma","year":"2008","unstructured":"Jongsma, J. et al. A conditional mouse model for malignant mesothelioma. Cancer Cell 13, 261\u2013271 (2008).","journal-title":"Cancer Cell"},{"key":"25173_CR56","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1101\/gr.197566.115","volume":"26","author":"V Gandin","year":"2016","unstructured":"Gandin, V. et al. nanoCAGE reveals 5\u2019 UTR features that define specific modes of translation of functionally related MTOR-sensitive mRNAs. Genome Res. 26, 636\u2013648 (2016).","journal-title":"Genome Res."},{"key":"25173_CR57","doi-asserted-by":"publisher","first-page":"7598","DOI":"10.1093\/nar\/gkr484","volume":"39","author":"R Elfakess","year":"2011","unstructured":"Elfakess, R. et al. Unique translation initiation of mRNAs-containing TISU element. Nucleic Acids Res. 39, 7598\u20137609 (2011).","journal-title":"Nucleic Acids Res."},{"key":"25173_CR58","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.molcel.2017.08.013","volume":"67","author":"M Morita","year":"2017","unstructured":"Morita, M. et al. mTOR controls mitochondrial dynamics and cell survival via MTFP1. Mol. Cell 67, 922\u2013935 (2017).","journal-title":"Mol. Cell"},{"key":"25173_CR59","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.cmet.2013.10.001","volume":"18","author":"M Morita","year":"2013","unstructured":"Morita, M. et al. mTORC1 controls mitochondrial activity and biogenesis through 4E-BP- dependent translational regulation. Cell Metab. 18, 698\u2013711 (2013).","journal-title":"Cell Metab."},{"key":"25173_CR60","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nrc.2017.42","volume":"17","author":"TA Yap","year":"2017","unstructured":"Yap, T. A., Aerts, J. G., Popat, S. & Fennell, D. A. Novel insights into mesothelioma biology and implications for therapy. Nat. Rev. Cancer 17, 475\u2013488 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"25173_CR61","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.1128\/MCB.01578-08","volume":"29","author":"MA Lopez-Lago","year":"2009","unstructured":"Lopez-Lago, M. A., Okada, T., Murillo, M. M., Socci, N. & Giancotti, F. G. Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling. Mol. Cell Biol. 29, 4235\u20134249 (2009).","journal-title":"Mol. Cell Biol."},{"key":"25173_CR62","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1158\/1541-7786.MCR-11-0425-T","volume":"10","author":"MF James","year":"2012","unstructured":"James, M. F. et al. Regulation of mTOR complex 2 signaling in neurofibromatosis 2- deficient target cell types. Mol. Cancer Res. 10, 649\u2013659 (2012).","journal-title":"Mol. Cancer Res."},{"key":"25173_CR63","doi-asserted-by":"publisher","first-page":"988","DOI":"10.3390\/ijms19040988","volume":"19","author":"T Sato","year":"2018","unstructured":"Sato, T. & Sekido, Y. NF2\/merlin inactivation and potential therapeutic targets in mesothelioma. Int J. Mol. Sci. 19, 988 (2018).","journal-title":"Int J. Mol. Sci."},{"key":"25173_CR64","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1128\/MCB.24.3.985-996.2004","volume":"24","author":"D Bertwistle","year":"2004","unstructured":"Bertwistle, D., Sugimoto, M. & Sherr, C. J. Physical and functional interactions of the Arf tumor suppressor protein with nucleophosmin\/B23. Mol. Cell Biol. 24, 985\u2013996 (2004).","journal-title":"Mol. Cell Biol."},{"key":"25173_CR65","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1128\/MCB.01307-06","volume":"27","author":"MS Lindstrom","year":"2007","unstructured":"Lindstrom, M. S., Jin, A., Deisenroth, C., White Wolf, G. & Zhang, Y. Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation. Mol. Cell Biol. 27, 1056\u20131068 (2007).","journal-title":"Mol. Cell Biol."},{"key":"25173_CR66","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.molcel.2010.03.015","volume":"38","author":"F Lessard","year":"2010","unstructured":"Lessard, F. et al. The ARF tumor suppressor controls ribosome biogenesis by regulating the RNA polymerase I transcription factor TTF-I. Mol. Cell 38, 539\u2013550 (2010).","journal-title":"Mol. Cell"},{"key":"25173_CR67","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nmeth.1314","volume":"6","author":"EK Schmidt","year":"2009","unstructured":"Schmidt, E. K., Clavarino, G., Ceppi, M. & Pierre, P. SUnSET, a nonradioactive method to monitor protein synthesis. Nat. methods 6, 275\u2013277 (2009).","journal-title":"Nat. methods"},{"key":"25173_CR68","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).","journal-title":"Nucleic Acids Res."},{"key":"25173_CR69","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1093\/bioinformatics\/btl476","volume":"22","author":"F Hong","year":"2006","unstructured":"Hong, F. et al. RankProd: a bioconductor package for detecting differentially expressed genes in meta-analysis. Bioinformatics 22, 2825\u20132827 (2006).","journal-title":"Bioinformatics"},{"key":"25173_CR70","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1261\/rna.060525.116","volume":"23","author":"T Sbarrato","year":"2017","unstructured":"Sbarrato, T. et al. An improved analysis methodology for translational profiling by microarray. RNA 23, 1601\u20131613 (2017).","journal-title":"RNA"},{"key":"25173_CR71","doi-asserted-by":"publisher","first-page":"W323","DOI":"10.1093\/nar\/gkr372","volume":"39","author":"AV Antonov","year":"2011","unstructured":"Antonov, A. V. BioProfiling.de: analytical web portal for high-throughput cell biology. Nucleic Acids Res. 39, W323\u2013W327 (2011).","journal-title":"Nucleic Acids Res."},{"key":"25173_CR72","doi-asserted-by":"publisher","first-page":"D851","DOI":"10.1093\/nar\/gkx1068","volume":"46","author":"DH Haft","year":"2018","unstructured":"Haft, D. H. et al. RefSeq: an update on prokaryotic genome annotation and curation. Nucleic Acids Res. 46, D851\u2013d860 (2018).","journal-title":"Nucleic Acids Res."},{"key":"25173_CR73","doi-asserted-by":"publisher","first-page":"D94","DOI":"10.1093\/nar\/gky989","volume":"47","author":"EW Sayers","year":"2019","unstructured":"Sayers, E. W. et al. GenBank. Nucleic Acids Res. 47, D94\u2013d99 (2019).","journal-title":"Nucleic Acids Res."},{"key":"25173_CR74","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-1206-5","volume":"9","author":"EB Affar","year":"2018","unstructured":"Affar, E. B. & Carbone, M. BAP1 regulates different mechanisms of cell death. Cell Death Dis. 9, 1151 (2018).","journal-title":"Cell Death Dis."},{"key":"25173_CR75","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/nature11083","volume":"485","author":"CC Thoreen","year":"2012","unstructured":"Thoreen, C. C. et al. A unifying model for mTORC1-mediated regulation of mRNA translation. Nature 485, 109\u2013113 (2012).","journal-title":"Nature"},{"key":"25173_CR76","doi-asserted-by":"publisher","first-page":"7507","DOI":"10.1073\/pnas.0810916106","volume":"106","author":"SE Calvo","year":"2009","unstructured":"Calvo, S. E., Pagliarini, D. J. & Mootha, V. K. Upstream open reading frames cause widespread reduction of protein expression and are polymorphic among humans. Proc. Natl Acad. Sci. USA 106, 7507\u20137512 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"25173_CR77","first-page":"26","volume":"6","author":"R Lorenz","year":"2011","unstructured":"Lorenz, R. et al. ViennaRNA Package 2.0. Algorithms. Mol. Biol. 6, 26 (2011).","journal-title":"Mol. Biol."},{"key":"25173_CR78","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1158\/2159-8290.CD-19-0620","volume":"10","author":"N Muthalagu","year":"2020","unstructured":"Muthalagu, N. et al. Repression of the type I interferon pathway underlies MYC- and KRAS-dependent evasion of NK and B cells in pancreatic ductal adenocarcinoma. Cancer Discov. 10, 872\u2013887 (2020).","journal-title":"Cancer Discov."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-25173-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-25173-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-25173-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T08:25:13Z","timestamp":1725611113000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-25173-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,13]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["25173"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-25173-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,13]]},"assertion":[{"value":"23 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests with the exception of the Murphy lab, which currently receives funding from Puma Biotechnology and the Merck Group for work unrelated to this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4920"}}